EUS-RFA for Unresectable Pancreatic Cancer
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Registration Number
- NCT04310111
- Lead Sponsor
- First People's Hospital of Hangzhou
- Brief Summary
The clinical application of intraoperative or percutaneous radiofrequency ablation (RFA) for pancreatic ductal adenocarcinoma (PDAC) is limited due to higher mortality and incidence of adverse events. The aim of this study was to evaluate the efficacy and safety of endoscopic ultrasonography-guided RFA (EUS-RFA) for locally advanced, unresectable PDAC. Patients with unresectable PDAC who underwent EUS-RFA were included from September 2013 to June 2016. Pre- and post-procedural clinical data was retrospective collected.
- Detailed Description
evaluate the efficacy and safety of endoscopic ultrasonography-guided RFA (EUS-RFA) for locally advanced, unresectable PDAC.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 8
- age 20 to 80 years old. ② unresectable PDAC based on review of abdominal cross-sectional imaging (CT or MRI) and cytology/ histology results. ③Intolerance to chemotherapy due to side effects or patient's comorbidities.
- Pregnancy or breast-feeding；②ECOG performance status 3 or 4；③Patients with distant metastases or malignant ascites, life expectancy less than 3 months.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Tumor size 2 years Tumor size
- Secondary Outcome Measures
Name Time Method Serum levels of CA19-9 2 years Serum levels of CA19-9 before and after surgery
Adverse events 2 years Adverse events
survival rate 2 years including Overall survival
Trial Locations
- Locations (1)
Hangzhou First People's Hospital
🇨🇳Hangzhou, Zhejiang, China
Hangzhou First People's Hospital🇨🇳Hangzhou, Zhejiang, China